ARWR
Price
$15.46
Change
+$0.14 (+0.91%)
Updated
May 22, 04:43 PM (EDT)
Capitalization
2.11B
81 days until earnings call
RARE
Price
$34.99
Change
-$0.42 (-1.19%)
Updated
May 22, 11:29 AM (EDT)
Capitalization
3.35B
70 days until earnings call
Interact to see
Advertisement

ARWR vs RARE

Header iconARWR vs RARE Comparison
Open Charts ARWR vs RAREBanner chart's image
Arrowhead Pharmaceuticals
Price$15.46
Change+$0.14 (+0.91%)
Volume$2.01K
Capitalization2.11B
Ultragenyx Pharmaceutical
Price$34.99
Change-$0.42 (-1.19%)
Volume$220
Capitalization3.35B
ARWR vs RARE Comparison Chart
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. RARE commentary
May 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and RARE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 22, 2025
Stock price -- (ARWR: $15.31 vs. RARE: $35.41)
Brand notoriety: ARWR: Notable vs. RARE: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 98% vs. RARE: 74%
Market capitalization -- ARWR: $2.11B vs. RARE: $3.35B
ARWR [@Biotechnology] is valued at $2.11B. RARE’s [@Biotechnology] market capitalization is $3.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $305.18B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, ARWR is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 6 bullish TA indicator(s).

  • ARWR’s TA Score: 5 bullish, 4 bearish.
  • RARE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, RARE is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а +2.68% price change this week, while RARE (@Biotechnology) price change was +1.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.75%. For the same industry, the average monthly price growth was +6.61%, and the average quarterly price growth was -2.20%.

Reported Earning Dates

ARWR is expected to report earnings on Aug 11, 2025.

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+3.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.35B) has a higher market cap than ARWR($2.11B). RARE YTD gains are higher at: -15.831 vs. ARWR (-18.564). RARE has higher annual earnings (EBITDA): -469M vs. ARWR (-580.69M). RARE has more cash in the bank: 610M vs. ARWR (553M). RARE has less debt than ARWR: RARE (40.3M) vs ARWR (525M). RARE has higher revenues than ARWR: RARE (560M) vs ARWR (2.5M).
ARWRRAREARWR / RARE
Capitalization2.11B3.35B63%
EBITDA-580.69M-469M124%
Gain YTD-18.564-15.831117%
P/E RatioN/AN/A-
Revenue2.5M560M0%
Total Cash553M610M91%
Total Debt525M40.3M1,303%
FUNDAMENTALS RATINGS
ARWR vs RARE: Fundamental Ratings
ARWR
RARE
OUTLOOK RATING
1..100
2213
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
4761
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (79) in the Biotechnology industry is in the same range as ARWR (94). This means that RARE’s stock grew similarly to ARWR’s over the last 12 months.

RARE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that RARE’s stock grew similarly to ARWR’s over the last 12 months.

RARE's SMR Rating (99) in the Biotechnology industry is in the same range as ARWR (100). This means that RARE’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's Price Growth Rating (47) in the Biotechnology industry is in the same range as RARE (61). This means that ARWR’s stock grew similarly to RARE’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for RARE (100). This means that ARWR’s stock grew significantly faster than RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRRARE
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 16 days ago
84%
Bearish Trend 9 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X109678.0800002886.992200
+2.70%
Bitcoin cryptocurrency
GME28.05-0.46
-1.61%
GameStop Corp
SPY582.86-9.99
-1.69%
SPDR® S&P 500® ETF
AAPL202.09-4.77
-2.31%
Apple
TSLA334.62-9.20
-2.68%
Tesla

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-6.02%
DNLI - ARWR
57%
Loosely correlated
-4.20%
NTLA - ARWR
56%
Loosely correlated
-4.86%
RGNX - ARWR
55%
Loosely correlated
-3.60%
BEAM - ARWR
54%
Loosely correlated
-2.99%
YMAB - ARWR
51%
Loosely correlated
-3.07%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with CRNX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-5.19%
CRNX - RARE
52%
Loosely correlated
-4.53%
RVMD - RARE
50%
Loosely correlated
-4.27%
COGT - RARE
50%
Loosely correlated
-6.21%
DNLI - RARE
50%
Loosely correlated
-4.20%
ARWR - RARE
49%
Loosely correlated
-6.02%
More